After these promising results, the combination of dabrafenib and trametinib was approved by the Food and Drug Administration (FDA) and the European Medical Agency (EMA) for advanced-stage NSCLC patients harboring a BRAF exon 15 p.V600E point mutation, irrespective of previous treatments [130,131]. Here, BRAF is linked to non-small cell lung carcinoma.